pulse2.com
Pan Cancer T B.V., a Rotterdam-based biotech developing next-generation T cell therapies for solid tumours, has raised €10 million to move its lead program, PCT1:CO-STIM, into a first-in-human clinical trial for women with triple-negative breast cancer, the company said on December 8, 2025. The financing combines €5 million from existing investors Van Herk Ventures, Thuja Capital, Erasmus MC O&O Holdings, and InnovationQuarter with a €5 million Innovation Credit loan from the Dutch Ministry of Economic Affairs. And it is intended to support patient treatment at leading cancer centres in the Netherlands.
9 days ago